{"title":"Ebastine in combination with low-dose antidepressants for refractory irritable bowel syndrome: A randomized controlled trial.","authors":"Chao Wang, Tengxiao Wang, Yangfang Chen, Wumei Lie, Fei Shen","doi":"10.1177/09287329251334289","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundDrug treatment of refractory irritable bowel syndrome (IBS) is not satisfactory at present. This study investigated the clinical effects of ebastine combined with low-dose antidepressants on refractory IBS.MethodsA total of 105 patients with refractory refractory IBS were randomly assigned to two different treatment groups after signing informed consent. And they didn't know about the treatment group they were in. They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. Drug efficacy was evaluated using scales before and after treatment. In addition, serum D-lactate (D-LAC) and human intestinal fatty acid binding protein (I-FABP) level were measured to assess intestinal permeability.ResultsSignificant improvements were observed in IBS Quality of Life (IBS-QOL) score, IBS Symptom Severity Scale (IBS-SSS) score, and total sleep quality score. Patients in Group A showed no improvements in anxiety (44.83 ± 9.62 <i>vs.</i> 43.92 ± 10.43, P = 0.415) and depression (39.08 ± 9.34 <i>vs.</i> 38.75 ± 9.35, P = 0.674) compared with the baseline level, while those in Group B improved significantly on anxiety (52.12 ± 8.19 <i>vs.</i> 39.28 ± 9.88) and depression (47.64 ± 9.53 <i>vs.</i> 38.24 ± 9.41) status. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.ConclusionRefractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients.</p>","PeriodicalId":48978,"journal":{"name":"Technology and Health Care","volume":" ","pages":"9287329251334289"},"PeriodicalIF":1.4000,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology and Health Care","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1177/09287329251334289","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
BackgroundDrug treatment of refractory irritable bowel syndrome (IBS) is not satisfactory at present. This study investigated the clinical effects of ebastine combined with low-dose antidepressants on refractory IBS.MethodsA total of 105 patients with refractory refractory IBS were randomly assigned to two different treatment groups after signing informed consent. And they didn't know about the treatment group they were in. They were administered with ebastine (Group A) or ebastine combined with flupentixol and melitracen (Group B) for 4 weeks. Drug efficacy was evaluated using scales before and after treatment. In addition, serum D-lactate (D-LAC) and human intestinal fatty acid binding protein (I-FABP) level were measured to assess intestinal permeability.ResultsSignificant improvements were observed in IBS Quality of Life (IBS-QOL) score, IBS Symptom Severity Scale (IBS-SSS) score, and total sleep quality score. Patients in Group A showed no improvements in anxiety (44.83 ± 9.62 vs. 43.92 ± 10.43, P = 0.415) and depression (39.08 ± 9.34 vs. 38.75 ± 9.35, P = 0.674) compared with the baseline level, while those in Group B improved significantly on anxiety (52.12 ± 8.19 vs. 39.28 ± 9.88) and depression (47.64 ± 9.53 vs. 38.24 ± 9.41) status. After treatment, the serum levels of D-LAC and I-FABP were significantly lower in Group B than in Group A.ConclusionRefractory IBS patients showed certain psychological abnormalities. Ebastine combined with antidepressants exhibited more obvious benefits on QOL, sleep quality, and SSS, with significant improvements in psychological status and intestinal permeability in refractory IBS patients.
期刊介绍：
Technology and Health Care is intended to serve as a forum for the presentation of original articles and technical notes, observing rigorous scientific standards. Furthermore, upon invitation, reviews, tutorials, discussion papers and minisymposia are featured. The main focus of THC is related to the overlapping areas of engineering and medicine. The following types of contributions are considered:
1.Original articles: New concepts, procedures and devices associated with the use of technology in medical research and clinical practice are presented to a readership with a widespread background in engineering and/or medicine. In particular, the clinical benefit deriving from the application of engineering methods and devices in clinical medicine should be demonstrated. Typically, full length original contributions have a length of 4000 words, thereby taking duly into account figures and tables.
2.Technical Notes and Short Communications: Technical Notes relate to novel technical developments with relevance for clinical medicine. In Short Communications, clinical applications are shortly described. 3.Both Technical Notes and Short Communications typically have a length of 1500 words.
Reviews and Tutorials (upon invitation only): Tutorial and educational articles for persons with a primarily medical background on principles of engineering with particular significance for biomedical applications and vice versa are presented. The Editorial Board is responsible for the selection of topics.
4.Minisymposia (upon invitation only): Under the leadership of a Special Editor, controversial or important issues relating to health care are highlighted and discussed by various authors.
5.Letters to the Editors: Discussions or short statements (not indexed).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
